Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Company Overview

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Key Stats

• Today's Range: $13.50 to $18.29
• 50-Day Range: $8.76 to $14.96
• 52-Week Range: $8.24 to $18.29
• Volume: 15.21 million shs
• Average Volume: 647,472 shs
• Market Capitalization: $745.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Buy

Mineralys Therapeutics Stock Analysis - MarketRank™

Mineralys Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 355th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Mineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mineralys Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mineralys Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mineralys Therapeutics is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mineralys Therapeutics has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.13% of the float of Mineralys Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mineralys Therapeutics has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Mineralys Therapeutics has recently decreased by 5.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mineralys Therapeutics does not currently pay a dividend.

Dividend Growth

Mineralys Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.13% of the float of Mineralys Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Mineralys Therapeutics has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Mineralys Therapeutics has recently decreased by 5.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.46

News Sentiment

Mineralys Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Mineralys Therapeutics this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $263,986.00 in company stock.

Percentage Held by Insiders

33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MLYS Stock Analysis - Frequently Asked Questions

How have MLYS shares performed this year?

Mineralys Therapeutics' stock was trading at $12.31 at the start of the year. Since then, MLYS stock has increased by 21.5% and is now trading at $14.96.
View the best growth stocks for 2025 here.

How were Mineralys Therapeutics' earnings last quarter?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02.

When did Mineralys Therapeutics IPO?

Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.

Who are Mineralys Therapeutics' major shareholders?

Top institutional shareholders of Mineralys Therapeutics include Orbimed Advisors LLC (3.24%), Vanguard Group Inc. (2.88%), Adams Street Partners LLC (2.27%) and Millennium Management LLC (2.21%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Hbm Healthcare Investments (Ca, Ra Capital Management, LP, Jon Congleton, Adam Scott Levy and David Malcom Rodman.
View institutional ownership trends.

How do I buy shares of Mineralys Therapeutics?

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mineralys Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/12/2025
• Today: 3/10/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MLYS
• CIK: 1933414
• Web: www.mineralystx.com
• Phone: 888-378-6240
• Fax: N/A
• Employees: 28
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $27.00
• High Stock Price Target: $30.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +80.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-177,810,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -67.97%
• Return on Assets: -62.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.02
• Quick Ratio: 14.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.84 per share
• Price / Book: 3.90

Miscellaneous

• Outstanding Shares: 49,836,000
• Free Float: 33,271,000
• Market Cap: $745.55 million
• Optionable: Optionable
• Beta: 1.50